{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:22:37Z","timestamp":1780089757392,"version":"3.54.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health"},{"name":"National Cancer Institute, National Institutes of Health","award":["75N91019D00024"],"award-info":[{"award-number":["75N91019D00024"]}]},{"name":"National Cancer Institute, National Institutes of Health","award":["75N91019F00130"],"award-info":[{"award-number":["75N91019F00130"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jaci.2020.11.005","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T23:14:38Z","timestamp":1605741278000},"page":"1004-1010.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis"],"prefix":"10.1016","volume":"147","author":[{"given":"Melody C.","family":"Carter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Maric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica H.","family":"Brittain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Lumbard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyejeong","family":"Bolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daly","family":"Cantave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda M.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean D.","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2020.11.005_bib1","series-title":"Anaphylaxis and anaphylactoid reactions","author":"Lieberman","year":"1998"},{"key":"10.1016\/j.jaci.2020.11.005_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1001\/archinte.161.1.15","article-title":"Anaphylaxis in the United States: an investigation into its epidemiology","volume":"161","author":"Neugut","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaci.2020.11.005_bib3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.iac.2007.03.009","article-title":"Idiopathic anaphylaxis","volume":"27","author":"Greenberger","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2020.11.005_bib4","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1001\/archinte.1990.00390180127023","article-title":"Idiopathic anaphylaxis: a clinical summary of 175 patients","volume":"150","author":"Wong","year":"1990","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaci.2020.11.005_bib5","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.immuni.2020.01.012","article-title":"Human mast cell proteome reveals unique lineage, putative functions, and structural basis for cell ablation","volume":"52","author":"Plum","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2020.11.005_bib6","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJM199912233412603","article-title":"Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group","volume":"341","author":"Milgrom","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2020.11.005_bib7","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1056\/NEJMoa022613","article-title":"Effect of anti-IgE therapy in patients with peanut allergy","volume":"348","author":"Leung","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2020.11.005_bib8","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaci.2007.06.015","article-title":"Anti-IgE treatment of eosinophil-associated gastrointestinal disorders","volume":"120","author":"Foroughi","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.11.005_bib9","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaci.2005.09.036","article-title":"Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis","volume":"117","author":"Casale","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.11.005_bib10","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jaip.2018.07.041","article-title":"Twelve-year follow-up of omalizumab therapy for anaphylaxis in 2 patients with systemic mastocytosis","volume":"7","author":"Constantine","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2020.11.005_bib11","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1346-8138.2012.01520.x","article-title":"Promising option in the prevention of idiopathic anaphylaxis: omalizumab","volume":"39","author":"Demirturk","year":"2012","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2020.11.005_bib12","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S1081-1206(10)60296-7","article-title":"Idiopathic anaphylaxis successfully treated with omalizumab","volume":"101","author":"Jones","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2020.11.005_bib13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5415\/apallergy.2014.4.2.126","article-title":"Successful prevention of recurrent anaphylactic events with anti-immunoglobulin E therapy","volume":"4","author":"Lee","year":"2014","journal-title":"Asia Pac Allergy"},{"key":"10.1016\/j.jaci.2020.11.005_bib14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.5152\/TurkPediatriArs.2017.2262","article-title":"Omalizumab\u2019s role in the treatment of steroid\u00a0dependent malignant idiopathic anaphylaxis","volume":"52","author":"Ozdemir","year":"2017","journal-title":"Turk Pediatri Ars"},{"key":"10.1016\/j.jaci.2020.11.005_bib15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jaci.2010.05.043","article-title":"Successful treatment of idiopathic anaphylaxis in an adolescent","volume":"126","author":"Pitt","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.11.005_bib16","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.anai.2019.09.020","article-title":"Treatment of idiopathic anaphylaxis with omalizumab","volume":"123","author":"Sanchez-Valenzuela","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2020.11.005_bib17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1081-1206(10)60091-9","article-title":"Omalizumab in idiopathic anaphylaxis","volume":"102","author":"Warrier","year":"2009","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2020.11.005_bib18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2340\/00015555-1687","article-title":"Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis","volume":"94","author":"Kibsgaard","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2020.11.005_bib19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.anai.2014.05.001","article-title":"Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome","volume":"113","author":"Jagdis","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2020.11.005_bib20","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.jaci.2017.07.013","article-title":"Anaphylaxis associated with omalizumab administration: risk factors and patient characteristics","volume":"140","author":"Lieberman","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.11.005_bib21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaci.2005.12.1303","article-title":"Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium","volume":"117","author":"Sampson","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.11.005_bib22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.anai.2015.07.019","article-title":"Anaphylaxis--a practice parameter update 2015","volume":"115","author":"Lieberman","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2020.11.005_bib23","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.resuscitation.2008.02.001","article-title":"Emergency treatment of anaphylactic reactions--guidelines for healthcare providers","volume":"77","author":"Soar","year":"2008","journal-title":"Resuscitation"},{"key":"10.1016\/j.jaci.2020.11.005_bib24","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2007.05.024","article-title":"KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1\/PDGFRA-associated chronic eosinophilic leukemia are distinct entities","volume":"120","author":"Maric","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.11.005_bib25","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jmoldx.2010.10.004","article-title":"Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay","volume":"13","author":"Kristensen","year":"2011","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jaci.2020.11.005_bib26","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1080\/01621459.1989.10478873","article-title":"Regression analysis of multivariate incomplete failure time data by modeling marginal distributions","volume":"84","author":"Wei","year":"1989","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jaci.2020.11.005_bib27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1001\/archinte.1987.00370020087042","article-title":"Clinical summary and course of idiopathic anaphylaxis in 73 patients","volume":"147","author":"Boxer","year":"1987","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaci.2020.11.005_bib28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1081-1206(10)63322-4","article-title":"Idiopathic anaphylaxis: a series of 335 cases","volume":"77","author":"Ditto","year":"1996","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2020.11.005_bib29","first-page":"370","article-title":"Clinical course of idiopathic anaphylaxis","volume":"73","author":"Khan","year":"1994","journal-title":"Ann Allergy"},{"key":"10.1016\/j.jaci.2020.11.005_bib30","series-title":"Concepts and principles of pharmacology: 100 years of the handbook of experimental pharmacology","first-page":"399","article-title":"Placebos and the placebo effect in drug trials","author":"Enck","year":"2019"},{"key":"10.1016\/j.jaci.2020.11.005_bib31","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jaci.2017.05.036","article-title":"A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis","volume":"141","author":"Carter","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.11.005_bib32","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/all.13366","article-title":"Identification of alpha-gal sensitivity in patients with a diagnosis of idiopathic anaphylaxis","volume":"73","author":"Carter","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2020.11.005_bib33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.iac.2015.01.004","article-title":"Idiopathic anaphylaxis","volume":"35","author":"Fenny","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2020.11.005_bib34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1081-1206(10)61367-1","article-title":"Anaphylaxis: a review of 601 cases","volume":"97","author":"Webb","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2020.11.005_bib35","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2013.08.016","article-title":"Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States","volume":"133","author":"Wood","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.11.005_bib36","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/all.13083","article-title":"Mechanisms of action that contribute to\u00a0efficacy of omalizumab in chronic spontaneous urticaria","volume":"72","author":"Kaplan","year":"2017","journal-title":"Allergy"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674920316201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674920316201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:31:41Z","timestamp":1758792701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674920316201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0091674920316201"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2020.11.005","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.739084871.793581655","asserted-by":"object"}]},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2020.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}